🩸 Heme/Onc Fellow @UToledo | 🏛️ Former Harvard Faculty | 📝 #Frontiers Editor | 🛂 VP @ASCO-CoP Visa Advocacy | 🤖 AI in Medicine |Creator #HemeOncSimplified
Toledo, OH
Joined October 2011
- Tweets861
- Following535
- Followers1.3K
- Likes2K
Wonderful!! Thanks @ADesaiMD 👇👇👇
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
➡️ OS 21.1 vs 12.7 mo, HR 0.42
➡️ PFS 7.4 vs 1.9 mo, HR 0.34
➡️ CRS 49.6% (G3+ 0.4%)
Amazing to be part of this practice-changing study on the global steering committee!!
@LungCancerRx @OncoAlert @oncodaily
🔬 ONC SPOTLIGHT — Jemperli for MSI-H/dMMR rectal cancer:71% drug alone, cCR12 47% · Keytruda TMB-H approval ≥13 mut/Mb,ORR 36% Camrelizumab TNBC pCR 57.5%, anthracycline-free📸 instagram.com/hemoncsimplifi… #HemeOncSimplified @IMG_Oncologists @HemOncFellows @UToledo @ASCO @oncodaily
🔥 ESMO 2026 Presidential Symposium — topics to watch: INTerpath-001 · TroFuse-005 · KEYNOTE-C93 · Krascendo 1 · VOLGA · DeLLphi-305 · SAFFRON. Results next week — · IG &🎙️ @HemoncSimplified ·
@HemOncFellows @IMG_Oncologists @ASCO @myESMO
ONC SPOTLIGHT — Fri Oct 16: Anktiva+BCG → papillary-only bladder cancer (CR 62%) · Inluriyo+Verzenio for ESR1-mut breast (PFS 11.1 vs 5.5 mo) · Lyrfigtu for FGFR2 bile-duct cancer (ORR 46%) follow @hemonc_dr - Insta #HemoncSimplified - podcast and Youtube for more updates!!!
Definitely one for the bookmarks! 📌 A remarkable contribution to #MultipleMyeloma! Huge kudos to @VincentRK for your relentless efforts, dedication, and continued impact on the field! 👏🏻🙏🏻 #Myeloma #MyelomaResearch
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
Dr. Schroff’s legacy lives🤍 on! Thank you, 🙌🏻NBC News, for the wonderful coverage! 👌🏻🙏🏻
Leading Cancer Researcher, 47, Dies of the Disease She Was Trying to Cure. This Was Her 1st Symptom nbcnews.com/health/disease/r… via @nbcnews
Such a tremendous loss to the GI Onc community!! 💔 Your courage, infectious smile, positivity, and unwavering dedication will forever inspire us. May you rest in eternal peace. Praying God grants your family strength and peace during this difficult time. 🤍🤍🤍🙏🏻@rachnatshroff
Devastating news 💔
Rest in peace dear Rachna.
medicine.arizona.edu/news/20…
🎯🤩 Excited to launch weekly news
🔬 ONC SPOTLIGHT
🧬 Adjuvant atezo in dMMR colon: HR 0.50
🎗️ Tucatinib maintenance in HER2+ mBC: PFS 24.9 vs 16.3 mo
💊 Camizestrant + CDK4/6i in ESR1m: PFS 16 vs 9.2 mo
🔬 Belzutifan + lenvatinib in RCC post-IO: PFS 14.6 vs 10.6 mo
Good to remember
And then in September 2026: we got 5 more new drugs/indications ✅ @FDADrugs!! As a #CommunityOncologists, we need to know them all:
1. #Camizestrant in mESR1 HR+ breast cancer (before progression). ⬆️mPFS (16mos vs. 9.2mos)
2. #Imlunestrant + #Abemaciclib in 2L metastatic mESR1 HR+ breast cancer. ⬆️mPFS (11.1mos vs. 5.5mos)
3. #Sevabertinib now in 1L Her2 mutated NSCLC. ORR 75%
4. #Lirafugratinib in 2L for FGFR2 fusion/rearrangement cholangiocarcinoma. ORR 46% and DoR 11.8mos
5. #Belzutifan + #Lenvatinib in 2L RCC. ⬆️mPFS (14.6mos vs. 10.6mos)
#OncTwitter #bcsm #lcsm #gusm @OncUpdates @FDA @US_FDA
Excellent to keep a note !!
Three things I recommend for using Bispecific antibodies in myeloma:
1) Prophylactic tocilizumab with first dose
2) Monthly IVIG regardless of the IgG level
3) Consider reducing frequency/stopping after excellent response.
This applies to all the approved bispecifics: teclistamab, elranatamab, linvoseltamab, and talquetamab.
Academic centers with expertise and close monitoring capabilities may skip the prophylactic tocilizumab but in general I do not see community adoption without it.
The data on routine IVIG and early use before the IgG levels drop or infections occur is good and sufficient to move forward. It’s recommended in NCCN and mSMART. Bispecifics are better at controlling myeloma than standard triplets and quads, but pose a much higher risk of serious life threatening infections without prophylaxis and careful adjustment of dosing schedule based on response and patient characteristics.
#IMS26
I’m incredibly honored and excited to see our core COGA project featured @ASCO Post, Cannot thank our mentors enough for their invaluable guidance and support 🙏🏻 @danae23 , Dr. Vijendra @GPMerugu @UToledo
ascopost.com/news/september-…
@realbowtiedoc @IMG_Oncologists @myCARG @JGeriOnc
Important updates 👇👇for August 2026 .. worth saving
What just happened in Oncology? 5 new drugs/indications ✅ @FDADrugs in August 2026. As a #CommunityOncologists, we need to know them all:
1. #Rusfertide in Polycythemia Vera, improved phlebotomy (76.9% vs. 32.9%)
2. #Daraxonrasib in 2L metastatic pancreatic cancer, mOS 13.2 Vs 6.7mos
3. #Zanidatamab + Chemo ± Tislelizumab in 1L metastatic Her2+ GEA/Gastric adenocarcinoma, mOS 26.4mos Vs 19.2mos
4. #Iberdomide + Dara + Dex in 2L RRMM, improved MRD negativity (41% vs. 21%)
5. #Vusolimogene + Nivo in refractory Melanoma. ORR of 24.2% and mDOR: 14.1mos.
#pancsm #mpnsm #OncTwitter #HemeTwitter @OncoAlert @OncUpdates
Important to remember 👇👇 for MM
With the revision of IMS IMWG high risk myeloma definition to make it stricter, and relaxation of diagnostic criteria for plasma cell leukemia to 5% PCs, the two groups have come closer in outcomes. They share a need for new ways overcome risk and improve prognosis with unified clinical trials. We also need to eliminate confusion for patients
In our view Plasma Cell Leukemia is a form of high risk myeloma. The term captures risk the same way del17 or EMD captures risk.
🧬 Flow Cytometry Demystified 🔬
🎥 Watch this video for a clear, practical approach to understanding how flow cytometry is used
🔗 Full video: youtu.be/cIS5W-ftVRY
#HematologyOncology #HemOnc #Immunophenotyping #MedEd @realbowtiedoc @HemOncFellows @IMG_Oncologists
Please check out 👇👇👇
🥁#Fellow #Resident #EarlyCareer friends! Check this out!
We're excited to be joined by #DrJonathanRogg to discuss one of the most important, yet often overlooked aspects of our personal and professional lives: #Financial #Wellness. His expertise will benefit not only #IMGs, but every trainee and early-career #oncologist.
Please spread the word and join us at 6 PM EST today!
🔗 tinyurl.com/bhdf788h
@IMG_Oncologists @ASCO @jrgralow @JasmineKambojMD @DrChoueiri @montypal @neerajaiims @ASCOTECAG @HemOncFellows @ZiadBakouny @OSUhemoncfellow @WCMHemOncFellow @SinaiHemeOnc @MoffittHemOnc @PittHemeOnc @AHNhemeonc @UChicagoHemOnc @CWRUHemeOnc @HemOncMiami @BIDMC_HOFellows @RoswellHemOnc @royaryam @AnaVManana @AmandaNizamMD @thenasheffect @PTarantinoMD #MedEd
🎙️ New Episode Alert!
🚨 Immune Checkpoint Inhibitors (ICIs) Simplified
From PD-1/PD-L1 & CTLA-4 to recognizing immune-related adverse events (irAEs) and their management—this episode breaks down one of the most important topics in modern oncology into practical, easy-to-understand concepts.
Perfect for:
👩⚕️ Medical students
🩺 Residents
🎓 Fellows
💉 Oncology clinicians
📚 Anyone learning immunotherapy
🎧 Listen here:
open.spotify.com/episode/78F…
❤️ If you enjoy the episode, please Like, Repost, and Follow to support HemOnc Simplified!
#HemOnc #Oncology #Immunotherapy #ImmuneCheckpointInhibitors #MedEd #FOAMed #MedicalEducation #Cancer #Hematology #InternalMedicine #OncologyTwitter #MedTwitter #MedX #MedicalStudents #Residents @realbowtiedoc @IMG_Oncologists @WimedicineOrg @WomeninOnc
Listen to ''HemeOnc Simplified'' on Spotify open.spotify.com/episode/4AQ…
🎙️ Excited to launch my new podcast series: 'HemeOnc Simplified!'
My goal is simple—make hematology and oncology easy, engaging, and fun to learn.
Whether you're a medical student, resident, Hematology/Oncology fellow, or simply interested in blood disorders and cancer medicine, this series breaks down complex topics into practical, easy-to-understand lessons you can apply in real clinical practice.
We'll cover:
🩸 AML, ALL, CML, CLL other hematological and solid malignancies
🧬 Molecular genetics made simple
🔬 Diagnosis & pathology
💊 Treatment algorithms & new therapies
📚 Board pearls & clinical decision-making
🎯 Real-world cases and evidence-based updates
Let's learn together, grow together, and ultimately provide better care for our patients.
I'd love your feedback, topic suggestions, and support. If you find it helpful, please like, repost, and share with your colleagues!
#HemeOnc #Hematology #Oncology #MedEd #FOAMed #MedicalEducation #MedTwitter #HematologyOncology #InternalMedicine #MedicalStudents #Residents #Fellows #AML #Leukemia #CancerEducation #EvidenceBasedMedicine #BoardReview #MedicalPodcast #MedX @HemOncFellows @IMG_Oncologists #HemeOncSimplified
Mamtha Balla, MD, MPH, FACP retweeted
A few combination options we touched on and have in upfront settings for metastatic RCC:
⭐️ Nivo/Ipi
⭐️ Nivo/Cabo
⭐️ Pembro/Axi
⭐️ Pembro/Len
** Single agent TKIs and Avelumab/Axi have fallen out of favor **
#OncTwitter #KidneyCancer #MedX #gusm
In our RCC “Challenging Case” discussion with @PBarataMD we touched on:
✅ 1L Rx options for metastatic RCC
✅ Sequencing in 2L and beyond
✅ Sequencing after Adj Rx
Full 🗣️:
⭐️ oncbrothers.com/cc-rcc-2026
⭐️ “Oncology Brothers” podcast
#OncTwitter #gusm #KidneyCancer